Incyte hit by CRL on extended-release JAK tablets, muddying plans for Jakafi franchise expansion

The FDA has rejected Incyte’s extended-release formulation of ruxolitinib tablets, in a surprise setback for the company’s plans to build on its blockbuster Jakafi franchise.